ImmunityBio Faces Securities Class Action After FDA Warning Letter Sinks Stock

What happened

A securities class action lawsuit has been filed against ImmunityBio (IBRX) alleging violations of federal securities laws between January 19 and March 24, 2026, covering the period when the company's stock dropped sharply after the FDA issued a warning letter for misleading promotional claims. The lawsuit adds legal overhang and potential settlement costs, but does not alter the fundamental commercial ramp thesis, which rests on ANKTIVA's revenue growth and the resolution of the OPDP matter. Q1 2026 net product revenue came in at $44.2M, up 15% sequentially, though operating cash burn remained high at $75.4M, underscoring the need for sustained revenue step-ups. The DeepValue master report rates IBRX a WAIT with conviction 3.0, citing balanced risk/reward and a base-case value of $9.50, with downside to $5.50 if OPDP escalates. The legal risk introduces incremental negative sentiment, but the stock remains priced for a commercial ramp that hinges on observable metrics like Q2 revenue and OPDP closure.

Implication

The class action adds downside asymmetry but does not break the commercialization thesis if revenue continues stepping up. Investors should monitor legal developments closely; any settlement could be manageable if revenue grows. The attractive entry at $7.00 offers margin of safety if legal headwinds fade, but conviction remains moderate until the OPDP issue is resolved and sequential revenue growth is confirmed.

Thesis delta

The class action lawsuit represents a new legal risk that could pressure the stock and distract management, but it does not change the fundamental investment case which hinges on ANKTIVA's commercial ramp and OPDP resolution. The probability of settlement costs and negative headlines increases, raising the required rate of return. However, the underlying revenue momentum and label expansion catalysts remain intact, so the WAIT rating and price targets are unchanged.